Stockscreener 앱 받기
3.82
4.95%
0.18
시간 외 거래:
3.82
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN
IOVA Deadline: IOVA Investors Have Opportunity to Lead Iovance B - GuruFocus
Macro Review: Will Iovance Biotherapeutics Inc benefit from green energy policiesDividend Hike & Verified Chart Pattern Trade Signals - baoquankhu1.vn
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
IOVA stock slump takes Wall Street, retail by surprise — here’s why - MSN
Iovance Biotherapeutics: Analyzing Growth Potential and Risks After Amtagvi Approval - IndexBox
Iovance Biotherapeutics (IOVA) Is Up 16.9% After Stronger Real-World Amtagvi Data Spurs Franchise Hopes - Sahm
A Melanoma Drug Successfully Launched, Yet Iovance’s Stock Has Underperformed the Market for Three Years - NAI500
IOVA Maintained by Chardan Capital -- Price Target Stays at $16 - GuruFocus
IOVA Stock Grinds Sideways As Traders Weigh Heavy Losses - timothysykes.com
Iovance Biotherapeutics Faces Stock Decline Amid Market Dynamics - Intellectia AI
Jefferies reiterates Iovance Biotherapeutics stock rating at buy By Investing.com - Investing.com Canada
Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
IOVA: Analyst Comments on FDA Rejection Impact - GuruFocus
Iovance Biotherapeutics (IOVA) Maintains Strong Outlook Amid Reg - GuruFocus
Iovance Biotherapeutics Faces Market Waves Amid Losses and Strategic Moves - timothysykes.com
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? - Yahoo Finance
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? - The Motley Fool
IOVA Stock Holds Key Support As Biotech Traders Circle - StocksToTrade
IOVANCE BIOTHERAPEUTICS INC (IOVA) Fundamental Analysis & Valuation - ChartMill
Iovance’s Landmark FDA Approval Shakes Up Melanoma Treatment Market - StocksToTrade
A Look At Iovance Biotherapeutics (IOVA) Valuation After Strong Amtagvi Data And Growing Pipeline Momentum - Sahm
Analyst sentiment remains strong on Iovance Biotherapeutics (IOVA) amid US rollout of melanoma drug, Amtagvi - MSN
Aug Fed Impact: How correlated is Iovance Biotherapeutics Inc to the S P5002026 Top Gainers & Community Shared Stock Ideas - baoquankhu1.vn
Market Review: How correlated is Iovance Biotherapeutics Inc to the S P500Portfolio Performance Summary & Low Risk High Reward Ideas - baoquankhu1.vn
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Below 50 Day Moving AverageHere's What Happened - MarketBeat
IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA) - Seeking Alpha
IOVA SEC FilingsIovance Biotherp 10-K, 10-Q, 8-K Forms - Stock Titan
Why Is Iovance Biotherapeutics, Inc. (IOVA) Stock Down Today? - Meyka
Iovance Biotherapeutics (IOVA) Is Down 6.5% After FDA Questions Amtagvi Marketing Claims Has The Bull Case Changed? - Sahm
Iovance Biotherapeutics Inc (IOVA) Stock Price, Quote, News & History - Benzinga
Why is Iovance Biotherapeutics Inc stock going up2026 Final Week & Real-Time Chart Breakout Alerts - baoquankhu1.vn
A Look At Iovance Biotherapeutics (IOVA) Valuation After FDA Concerns Over Amtagvi Marketing Practices - Sahm
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN
After IOVA stock’s best day in 2 years, analyst sees over 300% upside: Here’s why - MSN
Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help (NASDAQ:IOVA) - Seeking Alpha
Market Outlook: Is Iovance Biotherapeutics Inc a stock for growth or value investors2026 Buyback Activity & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Volume Recap: Is Iovance Biotherapeutics Inc still a buy after recent gains2026 Price Momentum & Growth Oriented Trading Recommendations - baoquankhu1.vn
IOVA | Iovance Biotherapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Iovance Biotherapeutics, Inc. $IOVA Stock Position Raised by Mirador Capital Partners LP - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Iovance Biotherapeutics (MIL:1IOVA) NonCurrent Deferred Rev - GuruFocus
Vanguard (IOVA) shows 0 shares after Jan 12, 2026 realignment - Stock Titan
Iovance downgraded to Neutral at UBS related to Amtagvi concerns - MSN
Q2 2025 Iovance Biotherapeutics Inc Earnings Call Transcript - GuruFocus
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Iovance Biotherapeutics (NASDAQ:IOVA) Rating Increased to Hold at Truist Financial - MarketBeat
Is It Time To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge - Yahoo Finance
Advanced Cell-based Therapy Booming the Success for Healthcare Sector - Sahm
Is Iovance Biotherapeutics (IOVA) Offering A Compelling Opportunity After Recent Price Swings? - sahmcapital.com
IOVA Technical Analysis | Trend, Signals & Chart Patterns | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference - simplywall.st
Iovance Biotherapeutics Announces Upcoming Board Member Retirement - The Globe and Mail
Iovance Biotherapeutics board member Wendy Yarno to retire after current term - Investing.com
2.69%
0.25%
자본화:
|
볼륨(24시간):